Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 6/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13666129 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL14970152 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL22122109 | 0.79 | KDR (0.59) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL23651807 | 0.79 | ALDH1A1 (0.55) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL6844994 | 0.79 | NCF1 (0.59) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL559347 | 0.79 | ALDH1A1 (0.55) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL30717270 | 0.77 | KMT2A (0.68) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL1160711 | 0.77 | KMT2A (0.68) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL30717271 | 0.77 | KMT2A (0.68) | ALDH1A1MEN1POLBRAB9AKMT2A | |
| SCHEMBL30717269 | 0.77 | KMT2A (0.68) | ALDH1A1MEN1POLBRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| EP-2909205-B1 | 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2705049-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-3039021-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| WO-2015031613-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| EP-2389376-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| US-20090258862-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258862-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2007027532-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | ALDH1A1 4235/4885MEN1 907/4885POLB 3109/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | ALDH1A1 4353/4885MEN1 2968/4885POLB 2563/4885 |
| US-20090258862-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | LDLR, APOB, FFAR1 | ALDH1A1 1477/4885MEN1 2777/4885POLB 3514/4885 |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ERBB2, ERBB3, AADAC | ALDH1A1 1370/4885MEN1 3766/4885POLB 2281/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | ALDH1A1 4353/4885MEN1 2968/4885POLB 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.